E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with type 1 diabetes with autonomic neuropathy or no 24h variation in bloodpressure. |
Patienter med type 1 diabetes med autonom neuropati eller ophævet døgnvariation i blodtryk |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with insulin dependant diabetes and nervesystem disorders and no 24h variation in bloodpressure |
Patienter med insulinkrævende sukkersyge og nerveforstyrrelser og ingen 24 timers variation i blodtryk. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Treatment of hypertension at nigth in patients with type 1 diabetes - with no 24h variation in bloodpressure implies a more suitable bloodpressure management, compared with conventional treatment (administration of drugs in the morning) |
Hypotese 1:
Natlig antihypertensiv behandling hos type 1 diabetes patienter med nedsat døgnblodtryksvariation giver en øget og mere hensigtsmæssig variation i døgnblodtrykket, sammenlignet med administration om morgenen. |
|
E.2.2 | Secondary objectives of the trial |
Nocturnal bloodpressure treatment has a measurable effect on cardiovasculare risk factors, including left ventricular mass. |
Hypotese 2:
Natlig antihypertensiv behandling har en målbar effekt på kendte kardiovaskulære risikofaktorer, herunder ventre ventrikels masse |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Type 1 diabetes
Age 18-65 years
HbA1C < 1%
Reduced heart rate variability
Reduced 24h bloodpressure variability
Normoalbinuria and no sigs of heartdisease |
Type 1 diabetes mellitus
Alder 18-65 år
HbA1C under 1%
Nedsat hjertefrekvensvariabilitet
Nedsat døgnvariation i blodtryk
Normoalbuminuri og ingen tegn på hjertesygdom
|
|
E.4 | Principal exclusion criteria |
Albinuria
Se-createnine>120 mikromol/l
Sleep apnea
Workload at nigth
A history of renal arthery stenosis or renal disease/nephrectimy
Primor angiooedema or serius sideeffects during treatment with ACE-inhibitors or ANG11 - antagonist
Everyday use of NSAID up to 4 weeks before inclusion
Bad compliance
Cancer or any other significant disease that could effect the trial
Women planning a pregnancy, are pregnant or nursing
Women who do not use contraception (contraceptive pill or IUD(Intra uterine device) |
Albuminuri
Serumcreatinin > 120 mikromol/l
Søvnapnø
Arbejdsforhold med stort antal nattevagter
Anamnese for nyreatreriestenose eller nyresygdom/nefretomi
Tidligere forekomst af angioødem eller alvorlige bivirkninger under behandling med Ace-hæmmer eller ANGII - antagonist
kronisk brug af NSAID, indtil 4 uger inden eventuel inklusion i forsøget
Enhver tilstand der vanskeliggør samarbejde omkring efterfølgelse af protokollen, udfra investigators vurdering.
Cancer eller anden klinisk signifikant sygdom eller lidelse, som efter investigators mening kan påvirke undersøgelsens resultater.
Kvinder der planlægger graviditet, er gravide, eller ammer
Kvinder, der ikke anvender præventionsmidler (p-piller eller IUD [intra uterine device])
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Noctuenal bloodpresure reduction by antihypertensive treatment at nigth comperred with drug administration in the morning |
Natlig blodtryksfald ved medicinadministration til natten i forhold til medicinadminstration om morgenen. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Left ventricular mass
Cardiac risk factors
Vibrationperception threshold |
Venstre ventrikels masse
Kardiologiske risikomakører i blodet
Tærskel værdi for vibrationssans på benene |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 0 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Date for First patient first visit 1.6.2012
Date for Last patient last visit 1.10.2013 |
Dato for Første patients første besøg 1.6.2012
Dato for Sidste patienst sidste besøg 1.10.2013
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |